Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.

Saved in:
Bibliographic Details
Title: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
Authors: Karim NA; Inova Schar Cancer Institute, Fairfax, Virginia; University of Virginia, Fairfax, Virginia. Electronic address: nagla.karim5@gmail.com., Miao J; SWOG Statistical Center and Data Management Center, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington., Reckamp KL; Cedars-Sinai Medical Center, Los Angeles, California; Department of Thoracic Head and Neck Medical Oncology, The University of Texas Maryland., Gay CM; Anderson Cancer Center, Houston, Texas., Byers LA; Anderson Cancer Center, Houston, Texas., Zhao YQ; SWOG Statistical Center and Data Management Center, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington., Redman MW; SWOG Statistical Center and Data Management Center, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington., Carrizosa DR; Levine Cancer Institute, Charlotte, North Carolina., Wang WL; Department of Pathology, MD Anderson Cancer Center, The University of Texas Houston, Texas., Petty WJ; Wake Forest College, Winston-Salem, North Carolina., Mehta K; Medstar Georgetown Cancer Institute, Washington, District of Columbia., Faller BA; Missouri Baptist Medical Center, Saint Louis, Missouri., Agamah ES; Southern Illinois University, Springfield, Illinois., Kasbari SS; Southeastern Medical Oncology Center, Goldsboro, North Carolina., Malisetti RK; Minnesota Oncology Hematology PA - Coon Rapids, Minneapolis, Minneapolis., Kumar A; University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico., Schallenkamp J; Billings Clinic, Billings, Motana., Alluri KC; St. Luke's Cancer Institute, Boise, Idaho., Gray JE; Moffitt Cancer Center, Tampa, Florida., Kelly K; UC Davis Comprehensive Cancer Center, Sacramento, California.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Mar; Vol. 20 (3), pp. 383-394. Date of Electronic Publication: 2024 Nov 04.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1556-1380
DOI:10.1016/j.jtho.2024.10.021